Barclays
DNA icon

Barclays’s Ginkgo Bioworks DNA Stock Holding History

Barclays’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$297K Buy
29,966
+21,988
+276% +$184K ﹤0.01% 3501
2026
Q1 		$48.9K Sell
7,978
-56,487
-88% -$470K ﹤0.01% 4330
2025
Q4 		$536K Buy
64,465
+6,665
+12% +$71.8K ﹤0.01% 3806
2025
Q3 		$843K Sell
57,800
-18,328
-24% -$219K ﹤0.01% 3470
2025
Q2 		$856K Buy
76,128
+28,712
+61% +$222K ﹤0.01% 3440
2025
Q1 		$270K Sell
47,416
-6,750
-12% -$68.8K ﹤0.01% 3886
2024
Q4 		$532K Buy
54,166
+42,224
+354% +$362K ﹤0.01% 3784
2024
Q3 		$97.3K Buy
11,942
+8,495
+246% +$85.1K ﹤0.01% 4582
2024
Q2 		$46.1K Sell
3,447
-6,227
-64% -$186K ﹤0.01% 4239
2024
Q1 		$449K Buy
9,674
+457
+5% +$23.7K ﹤0.01% 3663
2023
Q4 		$623K Sell
9,217
-166
-2% -$10.2K ﹤0.01% 3746
2023
Q3 		$679K Buy
9,383
+729
+8% +$58.3K ﹤0.01% 2600
2023
Q2 		$644K Sell
8,654
-11,001
-56% -$651K ﹤0.01% 2594
2023
Q1 		$1.05M Sell
19,655
-2,178
-10% -$138K ﹤0.01% 2700
2022
Q4 		$1.48M Buy
21,833
+2,754
+14% +$253K ﹤0.01% 2479
2022
Q3 		$2.38M Buy
19,079
+11,400
+148% +$1.36M ﹤0.01% 1629
2022
Q2 		$731K Buy
7,679
+6,693
+679% +$816K ﹤0.01% 2582
2022
Q1 		$159K Buy
+986
New +$192K ﹤0.01% 3557

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Barclays's DNA Position: Q2 2026 in Review

Barclays increased its Ginkgo Bioworks (DNA) stake by 276% in Q2 2026, buying an estimated $184K and bringing the position to 29,966 shares worth $297K. The position accounts for ﹤0.01% of the portfolio, ranked #3501.

Barclays first reported a position in DNA in Q1 2022 and has held it in 18 quarters since. The position peaked at $2.38M in Q3 2022. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Barclays held 29,966 shares of Ginkgo Bioworks worth $297K as of Q2 2026.
  • Barclays bought 21,988 Ginkgo Bioworks shares in Q2 2026, an estimated $184K.
  • Ginkgo Bioworks made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3501 holding.
  • Barclays first reported a position in Ginkgo Bioworks in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Ginkgo Bioworks position peaked at $2.38M in Q3 2022.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.